Phathom Pharma to Present VOQUEZNA® Data at DDW 2024

Phathom Pharmaceuticals, Inc., a leading biopharmaceutical company specializing in gastrointestinal (GI) diseases, has announced the presentation of new research findings at Digestive Disease Week® (DDW) 2024. This event, scheduled to take place from May 18-21 in Washington, D.C., will feature important data on their novel treatment VOQUEZNA® (vonoprazan).

The highlight of this presentation will be the first oral presentation of Phase 3 data evaluating the investigational use of VOQUEZNA in Non-Erosive Reflux Disease (NERD). Additionally, poster sessions will present real-world insights into treatment patterns and healthcare resource utilization among newly diagnosed patients with Erosive Gastroesophageal Reflux Disease (GERD), as well as the accuracy of diagnostic methods used to grade disease severity.

Eckhard Leifke, M.D., Chief Medical Officer at Phathom, emphasized the significance of this year's abstracts, noting that they demonstrate Phathom’s ongoing commitment to improving the lives of individuals with acid-related GI disorders. He expressed excitement about the novel findings and anticipated valuable engagements with physicians at the congress.

Phathom recently disclosed that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for VOQUEZNA as a daily treatment for heartburn associated with Non-Erosive GERD, with a Prescription Drug User Fee Act (PDUFA) target action date set for July 19, 2024.

In addition to the oral presentation and three poster sessions, Phathom will sponsor a product theater focusing on VOQUEZNA as an approved treatment for Erosive Esophagitis, also known as Erosive GERD. The company will also maintain a presence on the exhibit floor throughout the conference.

Phathom’s schedule at DDW 2024 includes a certified symposium on the latest treatments for Erosive Esophagitis and GERD, various poster sessions, and a notable oral presentation by Dr. Brooks D. Cash regarding vonoprazan for the treatment of heartburn in NERD.

Digestive Disease Week® (DDW) is the world's largest conference for professionals in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. This prominent event, co-sponsored by major associations such as the American Association for the Study of Liver Diseases (AASLD) and the American Gastroenterological Association (AGA) Institute, features over 3,500 abstracts and numerous lectures on the latest advancements in GI research and medicine.

VOQUEZNA, marketed exclusively by Phathom Pharmaceuticals, is a prescription medicine used in adults for the healing and maintenance of healing of all grades of Erosive Esophagitis (Erosive GERD) and for the relief of heartburn associated with Erosive GERD. VOQUEZNA contains vonoprazan, a potassium-competitive acid blocker (PCAB), which represents a novel class of stomach acid suppression medications.

Erosive GERD, a subtype of GERD, is characterized by erosions in the gastric mucosa due to acidic reflux. It is estimated that over 65 million individuals in the U.S. have GERD, with approximately 30% experiencing Erosive GERD. If inadequately treated, Erosive GERD can progress to more severe conditions such as Barrett’s esophagus and esophageal cancer.

Phathom Pharmaceuticals, headquartered in Florham Park, New Jersey, focuses on developing and commercializing innovative treatments for gastrointestinal diseases. The company has secured exclusive rights to vonoprazan in the U.S., collaborating with Takeda, which markets the product in Japan and other regions. Besides VOQUEZNA for Erosive GERD, Phathom also markets VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® for H. pylori infections in adults.

Through its pioneering research and comprehensive treatment solutions, Phathom Pharmaceuticals continues to be at the forefront of addressing unmet needs in gastrointestinal healthcare.